Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport

Annual Review of Physiology

Volumn 73, Issue , 2011, Pages 239-259

  Jia, Lin ^a   Betters, Jenna L ^a   Yu, Liqing ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ezetimibe; fat absorption; hepatic steatosis; obesity

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NIEMANN PICK C1 LIKE 1 PROTEIN; PHYTOSTEROL; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BILIARY EXCRETION; BINDING SITE; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; DRUG TARGETING; ENDOCYTOSIS; ENTEROHEPATIC CIRCULATION; GENETIC VARIABILITY; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; INTESTINE ABSORPTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DISTRIBUTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; BILIARY TRACT; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTEROL; ENDOCYTOSIS; FATTY LIVER; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MEMBRANE PROTEINS; MICE; OBESITY; PHYTOSTEROLS; PRIMATES;

EID: 79951793527     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-012110-142233     Document Type: Article

References (152)

1. Dawson AM, Isselbacher KJ. 1960. Studies on lipid metabolism in the small intestine with observations on the role of bile salts. J. Clin. Investig. 39:730-40
2. Hofmann AF, Borgstroem B. 1964. The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption. J. Clin. Investig. 43:247-57
3. Wang DQ. 2007. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol. 69:221-48 (Pubitemid 46457642)
4. van Der Velde AE, Vrins CL, Van Den Oever K, Kunne C, Oude Elferink RP, et al. 2007. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 133:967-75 (Pubitemid 47374133)
5. Kreisberg RA, Oberman A. 2002. Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J. Clin. Endocrinol. Metab. 87:423-37 (Pubitemid 34158199)
6. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. 2010. Heart disease and stroke statistics-2010 update. A report from the American Heart Association. Circulation 121:e46-215
7. Endo A. 1992. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid. Res. 33:1569-82
8. 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel onDetection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 106:3143-421
9. Grundy SM, Cleeman JI, Merz CN, BrewerHB Jr, Clark LT, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines. Circulation 110:227-39 (Pubitemid 38924592)
10. Rosenblum SB, Huynh T, Afonso A, Davis HR Jr, Yumibe N, et al. 1998. Discovery of 1- (4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]- (4S)-(4-hydroxyphenyl)-2- azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem. 41:973-80
11. Davis HR Jr, Compton DS, Hoos L, Tetzloff G. 2001. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 21:2032-38 (Pubitemid 34219758)
12. van Heek M, Farley C, Compton DS, Hoos L, Alton KB, et al. 2000. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. 129:1748-54 (Pubitemid 30219019)
13. DavisHR Jr, Pula KK, AltonKB, Burrier RE, Watkins RW. 2001. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 50:1234-41 (Pubitemid 33034709)
14. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, et al. 2002. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90:1084-91 (Pubitemid 35339435)
15. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, et al. 2002. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40:2125-34 (Pubitemid 36005898)
16. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, et al. 2004. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-4 (Pubitemid 38233587)
17. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, et al. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA 102:8132-37 (Pubitemid 40800055)
18. Weinglass AB, Kohler M, Schulte U, Liu J, Nketiah EO, et al. 2008. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. USA 105:11140-45
19. Davies JP, Levy B, Ioannou YA. 2000. Evidence for a Niemann-PickC(NPC) gene family: identification and characterization of NPC1L1. Genomics 65:137-45 (Pubitemid 30314421)
20. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, et al. 1997. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 277:228-31 (Pubitemid 27446076)
21. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, et al. 1997. Murine model of Niemann-Pick C disease: mutation in a cholesterol homeostasis gene. Science 277:232-35 (Pubitemid 27446077)
22. Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, et al. 2006. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem. 281:6616-24 (Pubitemid 43847596)
23. Yamanashi Y, TakadaT, SuzukiH. 2007. Niemann-Pick C1-like 1 overexpression facilitates ezetimibesensitive cholesterol and β-sitosterol uptake in CaCo-2 cells. J. Pharmacol. Exp. Ther. 320:559-64 (Pubitemid 46147934)
24. Iyer SP, Yao X, Crona JH, Hoos LM, Tetzloff G, et al. 2005. Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim. Biophys. Acta 1722:282-92 (Pubitemid 40354166)
25. Davies JP, Chen FW, Ioannou YA. 2000. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290:2295-98 (Pubitemid 32041568)
26. Wang J, Chu BB, Ge L, Li BL, Yan Y, Song BL. 2009. Membrane topology of human NPC1L1, a key protein in enterohepatic cholesterol absorption. J. Lipid Res. 50:1653-62
27. Kuwabara PE, Labouesse M. 2002. The sterol-sensing domain: multiple families, a unique role? Trends Genet. 18:193-201 (Pubitemid 34273740)
28. Radhakrishnan A, Sun LP, Kwon HJ, Brown MS, Goldstein JL. 2004. Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol. Cell 15:259-68 (Pubitemid 38950972)
29. Ohgami N, Ko DC, Thomas M, Scott MP, Chang CC, Chang TY. 2004. Binding between the Niemann-Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol-sensing domain. Proc. Natl. Acad. Sci. USA 101:12473-78 (Pubitemid 39122048)
30. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. 2005. Inactivation ofNPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280:12710-20
31. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, et al. 2007. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Investig. 117:1968-78 (Pubitemid 47036331)
32. Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. 2003. Inhibition of cholesterol absorption associated with a PPAR-α dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 44:2049-58 (Pubitemid 37509620)
33. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, et al. 2000. Regulation of absorption and ABC1- mediated efflux of cholesterol by RXR heterodimers. Science 289:1524-29
34. McNamara DJ, Davidson NO, Samuel P, Ahrens EH Jr. 1980. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J. Lipid Res. 21:1058-64 (Pubitemid 11183168)
35. Umeda Y, Kako Y, Mizutani K, Iikura Y, Kawamura M, et al. 2001. Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine. J. Lipid Res. 42:1214-19 (Pubitemid 32744244)
36. Vanhanen HT, Miettinen TA. 1995. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 115:135-46
37. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. 2003. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 278:15565-70 (Pubitemid 36799664)
38. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, et al. 2001. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98:5306-11 (Pubitemid 32397124)
39. vanDer Veen JN, Kruit JK, Havinga R, Baller JF, ChiminiG, et al. 2005. Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46:526-34 (Pubitemid 43109789)
40. Mathur SN, Watt KR, Field FJ. 2007. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J. Lipid Res. 48:395-404 (Pubitemid 46220606)
41. Valasek MA, Clarke SL, Repa JJ. 2007. Fenofibrate reduces intestinal cholesterol absorption viaPPARα- dependent modulation of NPC1L1 expression in mouse. J. Lipid Res. 48:2725-35 (Pubitemid 350272857)
42. DuvalC, Touche V, Tailleux A, Fruchart JC, Fievet C, et al. 2006. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 340:1259-63 (Pubitemid 43083413)
43. Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, et al. 2005. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128:147-56 (Pubitemid 40039966)
44. Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-40 (Pubitemid 27220877)
45. Horton JD, Goldstein JL, BrownMS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 109:1125-31 (Pubitemid 34496588)
46. DavisHRJr, ZhuLJ, HoosLM, Tetzloff G, MaguireM, et al. 2004. Niemann-PickC1Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279:33586-92 (Pubitemid 39063007)
47. Temel RE, Lee RG, Kelley KL, Davis MA, Shah R, et al. 2005. Intestinal cholesterol absorption is substantially reduced in mice deficient in both ATP-binding cassette transporter A1 (ABCA1) and acyl-CoA:cholesterol O-acyltransferase 2 (ACAT2). J. Lipid Res. 46:2423-31 (Pubitemid 41532530)
48. Liu R, Iqbal J, Yeang C, Wang DQ, Hussain MM, Jiang XC. 2007. Phospholipid transfer proteindeficient mice absorb less cholesterol. Arterioscler. Thromb. Vasc. Biol. 27:2014-21 (Pubitemid 47312312)
49. Tang W, Ma Y, Yu L. 2006. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. Hepatology 44:1259-66 (Pubitemid 44748376)
50. Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. 2007. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J. Lipid Res. 48:699-708 (Pubitemid 46397473)
51. AlrefaiWA, Annaba F, Sarwar Z, Dwivedi A, Saksena S, et al. 2007. Modulation of human Niemann- Pick C1-like 1 gene expression by sterol: role of sterol regulatory element binding protein 2. Am. J. Physiol. Gastrointest. Liver Physiol. 292:369-76
52. Pramfalk C, Jiang ZY, Cai Q, Hu H, Zhang SD, et al. 2010. HNF1α and SREBP2 are important regulators of NPC1L1 in human liver. J. Lipid Res. 51:1354-62
53. Iwayanagi Y, Takada T, Suzuki H. 2008. HNF4αis a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm. Res. 25:1134-41
54. Plosch T, Kruit JK, Bloks VW, Huijkman NC, Havinga R, et al. 2006. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J. Nutr. 136:2135-40 (Pubitemid 44156815)
55. Tso P, Fujimoto K. 1991. The absorption and transport of lipids by the small intestine. Brain Res. Bull. 27:477-82
56. Wilson MD, Rudel LL. 1994. Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J. Lipid Res. 35:943-55 (Pubitemid 24181099)
57. Turley SD, Dietschy JM. 2003. Sterol absorption by the small intestine. Curr. Opin. Lipidol. 14:233-40 (Pubitemid 36688201)
58. Grundy SM. 1983. Absorption and metabolism of dietary cholesterol. Annu. Rev. Nutr. 3:71-96
59. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, et al. 2000. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-75 (Pubitemid 32004809)
60. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, et al. 2001. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 27:79-83 (Pubitemid 32044523)
61. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, et al. 2002. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. USA 99:16237-42 (Pubitemid 35462779)
62. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, et al. 2002. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Investig. 110:671-80 (Pubitemid 34988791)
63. BrunhamLR, Kruit JK, Iqbal J, Fievet C, Timmins JM, et al. 2006. IntestinalABCA1directly contributes to HDL biogenesis in vivo. J. Clin. Investig. 116:1052-62
64. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. 2008. Niemann-Pick C1-Like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler. Thromb. Vasc. Biol. 28:448-54
65. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, et al. 1998. Identification of a form of acyl- CoA:cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J. Biol. Chem. 273:26747-54 (Pubitemid 28471691)
66. Ingram MF, ShelnessGS. 1997. Folding of the amino-terminal domain of apolipoprotein B initiates microsomal triglyceride transfer protein-dependent lipid transfer to nascent very low density lipoprotein. J. Biol. Chem. 272:10279-86 (Pubitemid 27171710)
67. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, et al. 1999. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Investig. 103:1287-98 (Pubitemid 29218299)
68. Grundy SM, Metzger AL. 1972. A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology 62:1200-17
69. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr. 1999. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. 40:302-8 (Pubitemid 29069805)
70. Small DM, Dowling RH, Redinger RN. 1972. The enterohepatic circulation of bile salts. Arch. Intern. Med. 130:552-73
71. Repa JJ, Dietschy JM, Turley SD. 2002. Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte. J. Lipid Res. 43:1864-74 (Pubitemid 35315804)
72. Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. 2005. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 46:1739-44 (Pubitemid 41099341)
73. Clarenbach JJ, Reber M, Lutjohann D, von Bergmann K, Sudhop T. 2006. The lipid-lowering effect of ezetimibe in pure vegetarians. J. Lipid Res. 47:2820-24 (Pubitemid 44936096)
74. Labonte ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, et al. 2008. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1/ mice. Am. J. Physiol. Gastrointest. Liver Physiol. 295:776-83
75. Dietschy JM, Turley SD, Spady DK. 1993. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34:1637-59 (Pubitemid 23298709)
76. Graf GA, Yu L, Li WP, Gerard R, Tuma PL, et al. 2003. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278:48275-82 (Pubitemid 37523283)
77. Klett EL, Lee MH, Adams DB, Chavin KD, Patel SB. 2004. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. BMC Gastroenterol. 4:21
78. Valasek MA, Repa JJ, Quan G, Dietschy JM, Turley SD. 2008. Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters. Am. J. Physiol. Gastrointest. Liver Physiol. 295:813-22
79. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ. 2008. Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Gastroenterology 134:2101-10 (Pubitemid 351790745)
80. Zuniga S, Molina H, Azocar L, Amigo L, Nervi F, et al. 2008. Ezetimibe prevents cholesterol gallstone formation in mice. Liver Int. 28:935-47 (Pubitemid 352044442)
81. Kovanen PT, Brown MS, Basu SK, Bilheimer DW, Goldstein JL. 1981. Saturation and suppression of hepatic lipoprotein receptors: a mechanism for the hypercholesterolemia of cholesterol-fed rabbits. Proc. Natl. Acad. Sci. USA 78:1396-400
82. Spady DK, Dietschy JM. 1988. Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster. J. Clin. Investig. 81:300-9 (Pubitemid 18075220)
83. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, et al. 2006. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA 103:1810-15 (Pubitemid 43228775)
84. Fahmi S, YangC, Esmail S, Hobbs HH, Cohen JC. 2008. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 17:2101-7 (Pubitemid 351911979)
85. Polisecki E, Peter I, Simon JS, Hegele RA, Robertson M, et al. 2010. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J. Lipid Res. 51:1201-7
86. Hegele RA, Guy J, Ban MR, Wang J. 2005. NPC1L1 haplotype is associated with interindividual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 4:16
87. Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, et al. 2005. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86:648-56 (Pubitemid 41752945)
88. Wang J, Williams C, Hegele R. 2005. Compound heterozygosity for two nonsynonymous polymorphisms in NPC1L1 in a nonresponder to ezetimibe. Clin. Genet. 67:175-77 (Pubitemid 40287525)
89. Chan DC, Watts GF, Wang J, Hegele RA, van Bockxmeer FM, Barrett PH. 2008. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin. Endocrinol. 69:45-51 (Pubitemid 351847259)
90. Martin B, Solanas-Barca M, Garcia-Otin AL, Pampin S, Cofan M, et al. 2010. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr.Metab. Cardiovasc. Dis. 20:236-42
91. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L. 2009. Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8. J. Lipid Res. 50:293-300
92. Davis HR Jr, Hoos LM, Tetzloff G, Maguire M, Zhu LJ, et al. 2007. Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE/ mice. Arterioscler. Thromb. Vasc. Biol. 27:841-49 (Pubitemid 46606715)
93. Brown JM, Rudel LL, Yu L. 2007. NPC1L1 (Niemann-Pick C1-like 1) mediates sterol-specific unidirectional transport of nonesterified cholesterol in McArdle-RH7777 hepatoma cells. Biochem. J. 406:273-83 (Pubitemid 47310958)
94. Ge L, Wang J, Qi W, Miao HH, Cao J, et al. 2008. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 7:508-19 (Pubitemid 351729203)
95. Petersen NH, FaergemanNJ, Yu L, Wustner D. 2008. Kinetic imaging of NPC1L1 and sterol trafficking between plasma membrane and recycling endosomes in hepatoma cells. J. Lipid Res. 49:2023-37
96. Weinglass AB, Kohler MG, Nketiah EO, Liu J, Schmalhofer W, et al. 2008. Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake. Mol. Pharmacol. 73:1072-84 (Pubitemid 351439189)
97. Sane AT, Sinnett D, Delvin E, Bendayan M, Marcil V, et al. 2006. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J. Lipid Res. 47:2112-20 (Pubitemid 44936122)
98. Labonte ED, Howles PN, Granholm NA, Rojas JC, Davies JP, et al. 2007. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim. Biophys. Acta 1771:1132-39 (Pubitemid 47404960)
99. Knopfel M, Davies JP, Duong PT, Kvaerno L, Carreira EM, et al. 2007. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane. Biochim. Biophys. Acta 1771:1140-47 (Pubitemid 47404961)
100. Brown JM, Rudel LL, Yu L. 2007. Niemann-Pick C1-like 1 (NPC1L1) mediates sterol-specific unidirectional transport of unesterified cholesterol inMcArdle-RH7777 hepatoma cells. Biochem. J. 406:273-83 (Pubitemid 47310958)
101. Larkin JM, Brown MS, Goldstein JL, Anderson RG. 1983. Depletion of intracellular potassium arrests coated pit formation and receptor-mediated endocytosis in fibroblasts. Cell 33:273-85 (Pubitemid 13096456)
102. Valasek MA, Weng J, Shaul PW, Anderson RG, Repa JJ. 2005. Caveolin-1 is not required for murine intestinal cholesterol transport. J. Biol. Chem. 280:28103-9 (Pubitemid 41076928)
103. Bonifacino JS, Traub LM. 2003. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu. Rev. Biochem. 72:395-447 (Pubitemid 36930451)
104. Betters JL, Yu L. 2010. Transporters as drug targets: discovery and development ofNPC1L1 inhibitors. Clin. Pharmacol. Ther. 87:117-21
105. Kwon HJ, Abi-Mosleh L, WangML, Deisenhofer J, Goldstein JL, et al. 2009. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell 137:1213-24
106. Betters JL, Yu L. 2010. NPC1L1 and cholesterol transport. FEBS Lett. 584:2740-47
107. Chu BB, Ge L, Xie C, Zhao Y, Miao HH, et al. 2009. Requirement of myosin Vb.Rab11a.Rab11- FIP2 complex in cholesterol-regulated translocation of NPC1L1 to the cell surface. J. Biol. Chem. 284:22481-90
108. Altmann SW, DavisHR Jr, Yao X, Laverty M, ComptonDS, et al. 2002. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim. Biophys. Acta 1580:77-93 (Pubitemid 34260848)
109. Smart EJ, De Rose RA, Farber SA. 2004. Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport. Proc. Natl. Acad. Sci. USA 101:3450-45
110. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, et al. 2005. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 280:1306-20
111. Mardones P, Quinones V, Amigo L, Moreno M, Miquel JF, et al. 2001. Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J. Lipid Res. 42:170-80 (Pubitemid 32206827)
112. Valasek MA, Weng J, Shaul PW, Anderson RG, Repa JJ. 2005. Caveolin-1 is not required for murine intestinal cholesterol transport. J. Biol. Chem. 280:28103-9 (Pubitemid 41076928)
113. Nguyen DV, Drover VA, Knopfel M, Dhanasekaran P, Hauser H, PhillipsMC. 2009. Influence of class B scavenger receptors on cholesterol flux across the brush border membrane and intestinal absorption. J. Lipid Res. 50:2235-44
114. Braun A, Yesilaltay A, Acton S, Broschat KO, Krul ES, et al. 2008. Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Atherosclerosis 198:77-84 (Pubitemid 351410545)
115. Hawes BE, O'Neill KA, Yao X, Crona JH, DavisHR Jr, et al. 2007. In vivo responsiveness to ezetimibe correlates with Niemann-Pick C1 like-1 (NPC1L1) binding affinity: comparison of multiple species NPC1L1 orthologs. Mol. Pharmacol. 71:19-29 (Pubitemid 46020974)
116. Salen G, Ahrens EHJr, Grundy SM. 1970. Metabolism of β-sitosterol in man. J. Clin. Investig. 49:952-67
117. Bhattacharyya AK, Connor WE. 1974. β-Sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J. Clin. Investig. 53:1033-43
118. SalenG, Shefer S, Nguyen L, Ness GC, TintGS, Shore V. 1992. Sitosterolemia. J. Lipid Res. 33:945-55
119. Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, et al. 2004. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109:966-71 (Pubitemid 38282848)
120. Salen G, Starc T, Sisk CM, Patel SB. 2006. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130:1853-57 (Pubitemid 43668834)
121. Turley SD. 2008. The role of Niemann-Pick C1-Like 1 (NPC1L1) in intestinal sterol absorption. J. Clin. Lipidol. 2:S20-28 (Pubitemid 351372950)
122. Yu L, von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. 2004. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 45:301-7 (Pubitemid 38228828)
123. Wang J, Sun F, Zhang DW, Ma Y, Xu F, et al. 2006. Sterol transfer by ABCG5 and ABCG8: in vitro assay and reconstitution. J. Biol. Chem. 281:27894-904 (Pubitemid 44414501)
124. Wang J, Zhang DW, Lei Y, Xu F, Cohen JC, et al. 2008. Purification and reconstitution of sterol transfer by native mouse ABCG5 and ABCG8. Biochemistry 47:5194-204 (Pubitemid 351620756)
125. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, et al. 2008. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358:1431-43 (Pubitemid 351482735)
126. Davis HR, Veltri EP. 2007. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 14:99-108
127. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. 1999. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-19 (Pubitemid 29258890)
128. Browning JD, Horton JD. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Investig. 114:147-52 (Pubitemid 39071617)
129. Cheung O, Sanyal AJ. 2009. Recent advances in nonalcoholic fatty liver disease. Curr. Opin.Gastroenterol. 25:230-37
130. Green RM. 2003. NASH: hepatic metabolism and not simply the metabolic syndrome. Hepatology 38:14-17 (Pubitemid 36775789)
131. Clark JM. 2006. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40(Suppl. 1):5-10
132. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. 2006. Prevalence of fatty liver in children and adolescents. Pediatrics 118:1388-93 (Pubitemid 46393782)
133. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-95 (Pubitemid 39657013)
134. Puri P, Baillie RA, WiestMM, Mirshahi F, Choudhury J, et al. 2007.Alipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46:1081-90 (Pubitemid 350144772)
135. Patil VS, Magar NG. 1960. Effect of dietary fat and cholesterol on the polyunsaturated fatty acids of cholesterol esters, phospholipids and triglycerides in the liver of the rat. Biochem. J. 74:441-44
136. Zheng S, Hoos L, Cook J, Tetzloff G, DavisHJr, et al. 2008. Ezetimibe improves high fat and cholesterol diet-induced nonalcoholic fatty liver disease in mice. Eur. J. Pharmacol. 584:118-24
137. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, et al. 2007. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 581:5664-70 (Pubitemid 350179776)
138. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, et al. 1996. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 13:18-19
139. Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. 2006. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with nonalcoholic fatty liver disease. World J. Gastroenterol. 12:4369-76 (Pubitemid 44194531)
140. Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, et al. 2009. Long-term combination therapy of ezetimibe and acarbose for nonalcoholic fatty liver disease. J. Hepatol. 51:548-56 140a
141. Jia L, Ma Y, Rong S, Betters JL, Xie P, et al. 2010. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J. Lipid Res. 51:3135-44
142. Chan DC, Watts GF, Gan SK, Ooi EM, Barrett PH. 2010. Effect of ezetimibe on hepatic fat, inflammatory markers and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care. 33:1134-39
143. Yoneda M, Fujita K, Nozaki Y, EndoH, Takahashi H, et al. 2010. Efficacy of ezetimibe for the treatment of nonalcoholic steatohepatitis: an open-label, pilot study. Hepatol. Res. 40:566-73
144. Enjoji M, Machida K, Kohjima M, Kato M, Kotoh K, et al. 2010. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for nonobese patients with nonalcoholic fatty liver disease. Lipids Health Dis. 9:29
145. Brown MS, Goldstein JL. 2008. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7:95-96 (Pubitemid 351168559)
146. Nomura M, Ishii H, Kawakami A, Yoshida M. 2010. Inhibition of hepatic Neiman-Pick C1-like 1 improves hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 297:1030-38
147. Yagi S, AkaikeM, Aihara K, Iwase T, Ishikawa K, et al. 2010. Ezetimibe amelioratesmetabolic disorders and microalbuminuria in patients with hypercholesterolemia. J. Atheroscler. Thromb. 17:173-80
148. Monetti M, Levin MC, Watt MJ, Sajan MP, Marmor S, et al. 2007. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6:69-78 (Pubitemid 46995777)
149. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. 1996. An oxysterol signaling pathway mediated by the nuclear receptor LXRα. Nature 383:728-31 (Pubitemid 26360651)
150. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, et al. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14:2831-38
151. Jia L, Ma Y, Liu G, Yu L. 2010. Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1. J. Lipid Res. 51:3024-33
152. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, et al. 2004. A multicenter, randomized, doubleblind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26:1758-73 (Pubitemid 40089489)